Search results for "Fluticasone-Salmeterol Drug Combination"

showing 6 items of 6 documents

Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma

2021

INTRODUCTION Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved on the market has been tiotropium. AREAS COVERED We reviewed recent clinical studies evaluating the safety and efficacy of LABA/LAMA/ICS fixed dose combinations by searching Pu…

Pulmonary and Respiratory Medicinemedicine.medical_specialtycorticosteroidFixed-dose combinationLABAAsthma corticosteroid fixed dose combination ICS inhaler LABA LAMA once daily combination uncontrolled asthmaMuscarinic Antagonistsonce daily combinationQuinolonesSettore MED/10 - Malattie Dell'Apparato RespiratorioinhalerAdrenal Cortex HormonesInternal medicineAdministration InhalationImmunology and AllergyMedicineHumansfixed dose combinationAdrenergic beta-2 Receptor AgonistsAsthmaFluticasonebiologyInhalationuncontrolled asthmabusiness.industryInhalerPublic Health Environmental and Occupational HealthLAMALamamedicine.diseasebiology.organism_classificationGlycopyrrolateFluticasone-Salmeterol Drug CombinationAsthmarespiratory tract diseasesDrug CombinationsICSIndansIndacaterolSalmeterolbusinessMometasone Furoatehormones hormone substitutes and hormone antagonistsmedicine.drug
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma

2010

BACKGROUND: Airway inflammation in asthma involves both large and small airways, and the combination of inhaled corticosteroids (ICS) and long acting beta-2 agonists (LABA) is the mainstay of therapy. Available inhaled combinations differ in terms of drug delivery to the lung and the ability to reach small airways. Aim: To evaluate whether treatment with an extra-fine inhaled combination provides additional effects vs a nonextra-fine combination on airway function. METHODS: After a 1- to 4-week run-in period, patients with asthma were randomized to a double blind, double dummy, 12-week treatment with either extra-fine beclomethasone/formoterol (BDP/F) 400/24 microg daily or fluticasone prop…

AdultMaleChemistry PharmaceuticalBeclomethasoneBronchiPilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthmaFluticasone-Salmeterol Drug CombinationRespiratory Function TestsAndrostadienesDrug CombinationsDouble-Blind MethodEthanolaminesForced Expiratory VolumeFormoterol FumarateAdministration InhalationHumansAsthma Therapy small airwaysAlbuterolFemaleAnti-Asthmatic AgentsMetered Dose InhalersBronchioles
researchProduct

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

2020

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m2, F/S: 2.855 mL/m2), with no statistically significant difference between treatments. However, T/O resulted…

Pulmonary and Respiratory Medicinemedicine.medical_specialtylcsh:MedicineFluticasone propionatePulmonary Disease Chronic Obstructive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFunctional residual capacityInternal medicinemedicineHumansMulticenter Studies as TopicPlethysmographIn patient1506030212 general & internal medicineTiotropium BromideLunginhaler devicesRandomized Controlled Trials as Topiclcsh:RC705-779COPDCross-Over Studiesbusiness.industrylcsh:ROlodaterollcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseFluticasone-Salmeterol Drug CombinationBenzoxazinesBronchodilator Agentsrespiratory tract diseasesrespiratory measurement030228 respiratory systemchemistryPerspectiveCardiologyCOPD pharmacologySalmeterolVentricular fillingbusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.

2011

SummaryRecommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate the efficacy of a newly developed fixed combination of ciclesonide and formoterol in comparison to the marketed fixed combination of fluticasone and salmeterol in patients with moderate asthma.This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to a 6-week treatment with ciclesonide/formoterol 320/9 μg bid (CIC/F) or fluticasone propionate/salmeterol 250/50 μg bid (FP/S), both delivered a…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUrologyCiclesonideCiclesonideFluticasone propionatechemistry.chemical_compoundYoung AdultDouble-Blind Methodimmune system diseasesPregnenedionesForced Expiratory VolumeFormoterol FumarateGermanyAdministration InhalationmedicineHumansFixed combinationAlbuterolFormoterolAnti-Asthmatic AgentsChildGlucocorticoidsFluticasoneAgedFluticasone-Salmeterol Drug Combinationbusiness.industryrespiratory systemMiddle AgedAsthmaFluticasone-Salmeterol Drug Combinationrespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilitychemistryEthanolaminesAustriaFormoterol FumarateFemaleSalmeterolFormoterolbusinessmedicine.drugRespiratory medicine
researchProduct

Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma

2010

Background: Airway inflammation in asthma involves both large and small airways, and the combination of inhaled corticosteroids (ICS) and long acting beta-2 agonists (LABA) is the mainstay of therapy. Available inhaled combinations differ in terms of drug delivery to the lung and the ability to reach small airways. Aim: To evaluate whether treatment with an extra-fine inhaled combination provides additional effects vs a nonextra-fine combination on airway function. Methods: After a 1- to 4-week run-in period, patients with asthma were randomized to a double blind, double dummy, 12-week treatment with either extra-fine beclomethasone/formoterol (BDP/F) 400/24 lg daily or fluticasone propiona…

Fluticasone-Salmeterol Drug CombinationInhalationClosing capacitybusiness.industryImmunologyrespiratory systemmedicine.diseaseFluticasone propionaterespiratory tract diseasesAnesthesiamedicineImmunology and AllergyMethacholineSalmeterolFormoterolbusinessAsthmamedicine.drugAllergy
researchProduct